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Abstract
Therapies consisting of a combination of agents are an attractive proposition, especially in the context of diseases such as
cancer, which can manifest with a variety of tumor types in a single case. However uncovering usable drug combinations is
expensive both financially and temporally. By employing computational methods to identify candidate combinations with a
greater likelihood of success we can avoid these problems, even when the amount of data is prohibitively large. HITTING SET is
a combinatorial problem that has useful application across many fields, however as it is NP-complete it is traditionally
considered hard to solve exactly. We introduce a more general version of the problem (a,b,d)-HITTING SET, which allows more
precise control over how and what the hitting set targets. Employing the framework of Parameterized Complexity we show
that despite being NP-complete, the (a,b,d)-HITTING SET problem is fixed-parameter tractable with a kernel of size O(adkd)
when we parameterize by the size k of the hitting set and the maximum number a of the minimum number of hits, and
taking the maximum degree d of the target sets as a constant. We demonstrate the application of this problem to multiple
drug selection for cancer therapy, showing the flexibility of the problem in tailoring such drug sets. The fixed-parameter
tractability result indicates that for low values of the parameters the problem can be solved quickly using exact methods.
We also demonstrate that the problem is indeed practical, with computation times on the order of 5 seconds, as compared
to previous Hitting Set applications using the same dataset which exhibited times on the order of 1 day, even with relatively
relaxed notions for what constitutes a low value for the parameters. Furthermore the existence of a kernelization for (a,b,d)-
HITTING SET indicates that the problem is readily scalable to large datasets.
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Introduction
Typically the selection of a drug therapy for a disease is limited
to a single drug, however diseases such as cancer may present as a
heterogeneous mix of subtypes of the general disease. In cases such
as these multi-drug therapies may prove more effective than single
drug therapies, and many trials have been conducted to this end
[1–3]. Furthermore combinations of drugs may allow a more
targeted approach for a selection of subtypes of a disease, while
minimizing effects on unaffected cells. Unfortunately with the
abundance of compounds available for the treatment of many
conditions of interest, the time and expense in testing even all two
drug combinations may be prohibitive. Therefore a smarter
approach is needed. Vazquez [4] introduces the HITTING SET
problem for this task in the context of oncological drug therapy.
The HITTING SET problem is a combinatorial problem that proves
extremely useful in modeling a large variety of problems in many
domains including protein network discovery [5], metabolic
network analysis [6], diagnostics [7–9], gene ontology [10] and
gene expression analysis [11,12].
The Hitting Set Problem
HITTING SET is a combinatorial problem that models the
problem of selecting a small group of elements to represent or
cover a collection of sets. Such a group that covers every set in the
collection is called a hitting set. Finding such a set without any
constraint is simple, however if we required that the size of the
hitting set be relatively small, the problem becomes computation-
ally challenging (NP-complete in a formal sense). This difficulty in
obtaining solutions with desirable qualities thus requires more
thoughtful approaches.
We now give some technical details and formal definitions of the
problems of interest.
HITTING SET is equivalent to the SET COVER problem [13], and
when otherwise unrestricted, is equivalent to the RED/BLUE
DOMINATING SET [14] problem and is related to the k-FEATURE
SET [15] problem.
The decision version of the HITTING SET problem is defined as
follows:
HITTING SET
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Question: Is there a set S’(S with DS’Dƒk such that for every
c[C we have c\S’=w?
The set S’ is called a hitting set for C, or simply a hitting set. For an
element s[S’ and an element C [C if s[c we say that s hits c.
This problem is NP-complete even when the maximum size of
each element of C is two (by equivalence with VERTEX COVER
[13]) and W½2 -complete for parameter k; Cotta and Moscato
[16] give a parameterized proof via k-FEATURE SET and Paz and
Moran [17] give a proof which along with the equivalence of
HITTING SET and SET COVER leads to the same result, though
predates the parameterized complexity framework. However if we
restrict the cardinality of the elements of C to d the problem, while
remaining NP-complete, becomes fixed-parameter tractable
where d is a constant and the parameter is k [18]. In this case
the problem is known as the HITTING SET FOR SETS OF SIZE d or d-
HITTING SET problem. We note that HITTING SET has several
equivalent formulations, in particular we choose to use the
bipartite graph representation where S and C form the two partite
vertex sets of the graph and an edge sc corresponds to the element
s[S being an element of c[C. This allows us to employ some
simplifying graph theoretic terminology and techniques. We
generalize this problem to include the case where we may want
the elements of C to be hit more than once. In particular this
includes the case where we ask if all the sets of C can be hit a
times, but extends to the case where the elements of C can be hit
up to a times. We encode this by the use of a hitting function g.
Our problem then becomes the a-MULTIPLE d-HITTING SET (or
(a,d)-HITTING SET):
(a,d)-HITTING SET
Instance: A bipartite graph G~(S ] C,E) where for all c[C
we have d(c)ƒd, a hitting function g : C?½0,a  and an
integer k.
Question: Is there a set S’(S with DS’Dƒk such that for every
c[C we have DN(c)\S’D§g(c)?
When g(c)~a for all c[C,( a,d)-HITTING SET can be (1zlnd)-
approximated in time O(a:DCD:DSD) [19], but cannot be approxi-
mated with a factor of (1{e)lnn for any e[(0,1) unless
NP(DTIME(nloglogn) [20].
Results and Discussion
The Fixed-Parameter Tractability of (a,d)-Hitting Set
As we prove in the Materials and Methods section, the (a,d)-
HITTING SET problem is fixed-parameter tractable, and indeed a
more general variant the (a,b,d)-HITTING SET problem is also fixed
parameter tractable when we take the maximum degree d of the
class vertices C as a constant and the size k of the hitting set and
the maximum desired coverage a as a joint parameter. Though the
problem is formally hard - which would normally give the intuition
that an exact solution would be too expensive to compute - the
fixed-parameter tractability indicates that it is likely that we can
obtain an exact solution efficiently. Armed with this knowledge we
proceed with the experiments of the following section, where we
use the drug response data of the NCI60 anti-tumor drug
screening program to determine a sets of drugs that hit cancerous
cell lines multiple times. These drug sets are than mathematically
supportable candidates for combination chemotherapies. More-
over we are able to tune the nature of the hitting sets via the
numbers k, a and b, which allows us to control which cell lines are
targetted (and which are specifically not) and how much each cell
line is hit in the solution.
A Comparative Application
The NCI60 human tumor anti-cancer drug screen dataset [21]
was established in the 1980s as an enabling tool for anti-cancer
drug development. Included in this dataset is response data for
over 40,000 drugs against the 60 cell lines of the dataset. Vazquez
[4] highlights the utility of a hitting set approach in developing
multi-drug therapies for heterogeneous malignancies; given the
plethora of available compounds, testing multi-drug combinations
exhaustively is prohibitive if not impossible. Applying hitting set to
efficacy data measured on an individual basis for each compound
allows us to determine possible drug combinations that would
provide the best chance of efficacy against many cancer types.
Using the GI50 response NCI60 dataset (available from the DTP
website [22]) Vazquez uncovers a minimum hitting set with three
compounds that cumulatively gives a good response with all cell
lines in the dataset, where a response is considered good if it is
more than two standard deviations above the mean of the z-
transformed response data. Vazquez uses first a greedy highest-
degree-first approach to give an estimate of the maximum size of a
minimum hitting set, followed by either an exhaustive search or
simulated annealing, depending on the size of the hitting set.
Vazquez reports times for such approaches on the order of one
day on a desktop computer.
We revisit Vasquez’s experiment, using data reduction (though
it is not necessary to employ the more complex rules given in the
kernelization proof) with IBM ILOG CPLEX [23] as the kernel
solver by framing the problem as a integer programming problem.
We use the same threshold for the z-transformation to identify
significant response levels. Using this approach we reduce the time
to solve the instance to less than 5 seconds, where most of the time
is spent loading and reducing the data, with CPLEX solving the
integer programming instance in approximately 0:08 milliseconds.
Furthermore this approach guarantees optimality in the size of the
hitting set.
From here we employ more a more recent version of the NCI60
dataset (2009 as compared to Vazquez’s 2006). At the time of
writing, the latest NCI60 dataset includes 14 additional cell lines,
however we remove these, as there is insufficient response data in
the dataset, leading to inflated hitting set sizes. The latest data also
includes a further 2281 compounds. We note that employing the
new GI50 response data we are able to uncover 3 element hitting
sets involving compounds not available in the earlier dataset (an
example is given in Table 1 and Figure 1), in particular Everolimus
(NSC 733504) a drug now used for the treatment of advanced
renal cancer which is also giving positive results in phase II trials
for metastatic melanoma [24,25]. However there have recently
been some concerns over the provenance of some of the cell lines
in the NCI60 dataset. In particular Lorenzi et al. [26] suggested
that the MDA-N cell line, nominally a breast cancer cell line is in
fact similar the M14 and MDA-MB-435 cell lines, and thus should
be is in fact a melanoma cell line. Chambers [27] however suggests
that although M14 and MDA-MB-435 are identical cell lines, they
may not in fact be melanoma cell lines. We do not attempt to
resolve this dispute, however with regard to this, and as a
indication of the flexibility of the method we employ we consider
both the case where MDA-N is a breast cancer cell line and the the
case where MDA-N is a melanoma cell line.
Employing the (a,b,d)-HITTING SET model gives more flexibility
in what kind of therapy we would like to pursue. For instance, by
choosing g1~2 for all vertices, we are able to find a hitting set that
hits every cell line at least twice (see Table 2). However the size of
Hitting Set and Drug Therapy
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trade off between anti-cancer efficacy and side effects is
acceptable. Fortunately we can exploit (a,b,d)-HITTING SET more
intelligently. For example we may wish to find a hitting set that
specifically targets breast cancer cell lines – for which we set all
breast cancer cell line vertices to have g1~1 and all other cell lines
to have g2~0. This gives a hitting set that hits only breast cancer
cell lines, which may be useful in minimizing unwanted peripheral
damage to non-breast cancer cells. This gives a hitting set with
three elements. In the case where we considered MDA-N to be a
breast cancer cell line (see Table 3 and Figure 2) this set includes
the compound deoxypodophyllotoxin, which is known to induce
apoptosis [28]. If we consider MDA-N as a melanoma cell line we
obtain a different hitting set (see Table 4 and Figure 3). If we relax
our requirements an allow other cell lines to be hit at most once we
can obtain a hitting set that hits the breast cancer cell lines more
(Table 5 and Figure 4). The results when we set g1 to 2 for all
breast cancer lines are given in Table 6 and Figure 5 (including
MDA-N) and Table 7 and Figure 6 (excluding MDA-N). We note
particularly that in the case where MDA-N is included, the
optimal hitting set uncovered includes Docetaxel, a well known
anti-cancer agent [29] for several cancer types including breast
cancer. Interestingly Docetaxel is also currently included in several
clinical trials examining its potential as part of a multi-drug
therapy [30–34].
In another example, we may wish to target melanoma cell lines
exclusively, and furthermore, we may wish to attack each cell line
with at least two drugs at once. However in this case (where g1~2
for melanoma cell lines and g2~0 for all others) the minimal
hitting set size is 6 (or 5 if MDA-N is included as a melanoma cell
line – Table 8 and Figures 7 & 8). Considering that a therapeutic
cocktail involving 6 compounds may have excessive side effects, we
can relax the requirements, and allow g2~1 for non-melanoma
cell lines. In this case we find that the smallest hitting set is of size
3. By altering the focus when solving the kernel by fixing the
hitting set size (k)a t3 and maximizing the total degree of the
vertices in the hitting set, subject to the g1 and g2 constraints, we
can obtain the minimal size hitting set that hits our targets as much
as possible, within the bounds given by the constraints. This results
in the hitting sets in Tables 9 & 10 and Figures 9 & 10. Of note is
AZD6244, which is currently involved in 21 anti-cancer drug trials
[35] and has been identified as a potent kinase inhibitor [36,37].
Conclusion
Given the size of modern datasets, and the expectation that they
will only get larger, it is clear that we require efficient approaches
to solving important computational biology problems. The first
phase of any such approach is simply defining the problem at
hand. Unfortunately once clearly stated, many such problems are
NP-hard or worse. However this need not mean that we must
resort to inexact or approximate approaches, which could be
undesirable in a field such as drug selection. Parameterized
Complexity provides a toolkit for dealing with nominally hard
problems, and identifying cases where despite super-polynomial
running times, we may still expect good performance.
The drug selection problem as examined here is one such
problem. It is modeled well by the d-HITTING SET problem, which
is fixed-parameter tractable when parameterized by the maximum
size of the hitting set. Therefore we can expect that despite being
NP-complete, it would be relatively quick to solve when these
parameters are small. However we demonstrate that the much
more flexible variant (a,b,d)-HITTING SET is also fixed-parameter
tractable, with only the addition of a single parameter - the
maximum of the minimum number of times any vertex should be
hit. With (a,b,d)-HITTING SET we are able to better control the
nature of the hitting set uncovered, and thus tailor any such hitting
set to a useful set of constraints, such as limits on which cell lines
are to be hit, the maximum any of these can be hit and of course
the minimum number of times any cell line should be hit.
Moreover we can solve this problem quickly, and guarantee
optimality - without any notable restrictions on the parameters
and constants. This allows the quick generation of possible drug
combinations for testing, with guarantees of a certain baseline
performance, eliminating the need to exhaustively test all possible
combinations, which would be financially and temporally
prohibitive.
In brief this paper provides a robust and flexible methodology
for multiple drug selection, which can easily be applied to other
domains that are modeled by the d-HITTING SET problem, with a
sound theoretical background as to why and how the problem can
be solved efficiently, despite its NP-completeness. Moreover the
existence of a kernelization for (a,b,d)-HITTING SET indicates that
even without using a specialized commercial solver such as
CPLEX, the problem is readily scalable to large datasets. Given
the speed at which we are able to solve instances with on the order
of 40,000 vertices, we can expect that much larger datasets are also
solvable in a reasonable time.
A future extension that may be of interest would be to somehow
encode in the problem the notion that some hitting vertices are
incompatible, e.g., two compound may have severe adverse
interactions, and thus can never be used together as a therapy,
regardless of their individual usefulness.
Materials and Methods
Dataset and Computational Method
The dataset primarily employed is the NCI60 DTP Human
Tumor Cell Line Screen, available from [22]. We use the version
released in October 2009, and downloaded in April 2010. The raw
dataset is presented as a series of cell line and compound pairs,
along with the GI50 response measurement (the method for
producing the measurements is also detailed by [22]) for that pair
plus concentration information and statistical information. Where
there are multiple entries for the same compound-cell line pair, we
Table 1. Minimal hitting set using 2009 NCI60 data.
NSC Number Compound Name
174121 Methotrexate Derivative
691039 (S)-7-Hydroxy-1,2,3-trimethoxy-10-methylsulfanyl-6,7-dihydro-5H-benzo[a]heptalen-9-one
733504 Everolimus/Afinitor
Minimal hitting set for NCI60 GI50 response data from 2009.
doi:10.1371/journal.pone.0013055.t001
Hitting Set and Drug Therapy
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concentration of the compound. We extract this data into a matrix
cross indexed by the NSC number of the compound and the name
of the cell line. Where an entry does not exist for a given
compound-cell line pair, we enter ‘‘NA’’ for that entry in the
matrix.
Once the data is in this matrix format we threshold the data
according to the method used by Vazquez [4] whereby the raw
data is subject to a z-transformation over a logarithmic scale and
then any value above a certain threshold expressed in terms of the
standard deviation to 1, and anything below, including ‘‘NA’’
values, to 0. In line with Vazquez we choose two standard
deviations as our particular threshold for this paper, though this is
adjustable.
We then construct a graph for the hitting set instance using the
Java Universal Network/Graph Framework (JUNG) [38] with the
SetHypergraph class, representing each compound with a vertex
and each cell line with a (hyper)edge which carries a weight
indicating the number of times that edge is to be hit. This graph is
then reduced to remove vertices of zero degree, edges with no
incident vertices (which are noted as technically this would
indicate a no instance unless that edge does not require hitting)
and vertices that are only adjacent to edges that require zero hits.
This basic reduction alone typically reduces the number of vertices
significantly, bringing the graph within a reasonable size for
immediate processing. From a theoretical standpoint the constant
d is of importance, for the graph constructed as stated, d~4741
(as we allow the natural value, rather than imposing an external
limit). In practice a d value of this magnitude proves perfectly
workable, and returning to the theoretical viewpoint indicates that
the instance is in a sense already kernelized.
Once the graph is reduced, we construct an integer program-
ming instance equivalent of the problem given the graph, and pass
this instance to CPLEX [23] (version 11.200) and search for an
optimal solution to one of two objective functions, given the
constraints of the number of hits for each cell line (given by the g1
value). The first objective function simply minimizes the size of the
hitting set (k), for the second objective function we fix the size of
the hitting set, and maximize the number of hits on vertices where
no maximum number of hits has been set (the g2 value). As part of
this search CPLEX may apply some unspecified proprietary
reduction process.
The figures were created using yEd Graph Editor [39].
The computer hardware employed is a Dell PowerEdge III
Dual Xeon 5550 server with 32Gb of RAM, operating Red Hat
Linux 64 bit EL 4 Server.
Theoretical Background and Kernelization Proof
Graph Theory and Notation. A (simple undirected) graph
consists of a set V (the vertices), and a set E of two element
subsets of V (the edges). A bipartite graph is a graph where the
vertices are partitioned into two partite sets, where all edges have
one endpoint in one set and the other endpoint in the other set,
i.e., V~V1 ] V2 and E(V1|V2.
Given a graph G~(V,E) and two vertices u,v[V, we denote
the edge between u and v by uv or equivalently vu. Given two
vertices u,v in V, if there is an edge uv[E we say that u and v are
Figure 1. Minimal hitting set hitting for the NCI60 dataset. This
hitting set hits all cell lines at least once, but is further optimized to hit
all target cell lines the maximal number of times. Of particular note are
NSC 174121, a methotrexate derivative and NSC733504, Everolimus/
Afinitor, both known anti-cancer agents.
doi:10.1371/journal.pone.0013055.g001
Hitting Set and Drug Therapy
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13055Table 2. Minimal double hitting set.
NSC Number Compound Name
147340 Anisomycin hydrochloride
174121 Methotrexate derivate
314018 Ansamitocin derivate TN-006
691039 (7S)-7-hydroxy-1,2,3-trimethoxy-10-methylsulfanyl-6, 7-dihydro-5H-benzo[a]heptalen-9-one
712807 Capecitabine
733504 Everolimus/Afinitor
Minimal hitting set hitting each cell line at least twice.
doi:10.1371/journal.pone.0013055.t002
Table 3. Minimal hitting set targeting only breast cancer.
NSC Number Compound Name
403148 Deoxypodophyllotoxin
697188 2-(4-methoxyphenyl)-5-[8-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]octyl]-1,3,4-oxadiazole
732011 21-(2-N,N-Diethylaminoethyl)oxy-7.alpha.-methyl-19-norpregna-1,3,5(10)-triene-3-O-sulfamate
Minimal hitting set hitting breast cancer cell lines at least once, and all other cell lines zero times.
doi:10.1371/journal.pone.0013055.t003
Figure 2. Minimal hitting set hitting only breast cancer cell lines. Including the disputed MDA-N cell line. This hitting set also reveals
additional structure with each drug targeting a specific, disjoint subset of the breast cancer cell lines. Only cell lines with at least one adjacent
compound are shown.
doi:10.1371/journal.pone.0013055.g002
Table 4. Minimal hitting set targeting only breast cancer without MDA-N.
NSC Number Compound Name
630678 Streptomyces antibiotic
732011 21-(2-N,N-Diethylaminoethyl)oxy-7.alpha.-methyl-19-norpregna-1,3,5(10)-triene-3-O-sulfamate
734235 isoindolo[1,2-a]quinoxalin-4(5H)-one
Minimal hitting set hitting breast cancer cell lines at least once, and all other cell lines zero times.
doi:10.1371/journal.pone.0013055.t004
Hitting Set and Drug Therapy
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set N(u) is the (open) neighborhood of u and consists off all vertices
adjacent to u in G, we extend this notion in the natural way to sets
of vertices.
Parameterized Complexity. A parameterized (decision) problem
is a formally defined computational problem consisting of three
components; the input, a special part of the input called the
parameter, and the question. Following Flum and Grohe’s [40]
definition we may assume that the parameter is derived from a
polynomial time computable mapping from the input to the
natural numbers. A parameterized problem P is fixed-parameter
tractable if there is an algorithm A such that for every instance (x,k)
where x is the input, k is the parameter and DxD~n, A correctly
answers YES or NO in time bounded by f(k)p(n) where p is a
polynomial and f is a computable function.
A polynomial time kernelization (or just kernelization) is a polynomial
time mapping that given an instance (x,k) of a parameterized
problem produces a new instance (x’,k’) of the problem such that:
1. x is a YES-instance if and only if x’ is a YES-instance,
2. k’ƒk and
3. Dx’Dƒg(k’) for some computable function g.
It is easy to see that if a problem has kernelization, then it is
fixed-parameter tractable. It is also easy to prove that if a problem
is fixed-parameter tractable, then it has a kernelization [41].
Parameterized complexity has a fully developed theory for
determining when a problem is unlikely to be fixed-parameter
tractable, but as this is not necessary for this work, we refer the
reader to the monographs of Flum and Grohe [40] and Downey
and Fellows [42] for full discussion, and simply state that if a
problem is W½t -hard or W½t -complete for any t[N
z, then the
problem is not fixed-parameter tractable unless certain complexity
theoretic assumptions are false, which seems unlikely.
The Fixed-Parameter Tractability of (a,d)-Hitting Set
Our kernelization for (a,d)-HITTING SET follows the basic format
of Abu-Khzam’s kernelization for d-HITTING SET [18].
Let (G,k) be an instance of (a,d)-HITTING SET which we assume
to have been preprocessed for nonsense input such as vertices
c[C with d(c)wd or d(c)vg(c). Therefore we may assume that
for all c[C we have g(c)ƒd(c)ƒd and that for all vertices s[S
we have d(s)§0.
We first apply Reduction Rules 1 to 3 exhaustively, before
applying Rules 4 and 5.:
Reduction Rule 1: If there is a vertex c[C with d(c)~g(c)
then for every vertex s[N(c) for every vertex b[N(s) reduce g(b)
by 1, delete s from G and reduce k by 1. Finally, delete c from G.
Lemma 1 Reduction Rule 1 is sound.
Proof. If such a vertex c exists, then all its neighbors in S must be
in the hitting set, and we can remove them from the graph after
suitably noting the effect for the vertices of N(N(c)).
Note in particular that this rule effectively allows us to assume
that m is at most d{1. This will be used implicitly in Reduction
Rule 4.
Reduction Rule 2: If there is a vertex c[C with g(c)~0,
delete c from G.
Lemma 2 Reduction Rule 2 is sound.
Proof. Clearly c requires no vertices to hit it, so may be
ignored.
Reduction Rule 3: If there are two vertices c,b[C such that
N(c)(N(b) and g(c)§g(b), delete b from G.
Lemma 3 Reduction Rule 3 is sound.
Proof. If two such vertices c and b exist, then any hitting set that
hits c at least g(c) times will hit b at least g(b)vg(c) times.
Let B(S be a set of size d{1 vertices such that B is the
pairwise intersection of the neighborhoods of a vertex set N(C.
Let Ni~fn[NDg(n)~ig.
Reduction Rule 4: Let B(S and N(C be vertex sets as
described. For each i[½1,a  such that DNiDwk add a vertex c to C
with g(c)~i and edges such that N(c)~B and delete Ni from G.
Lemma 4 Reduction Rule 4 is sound.
Proof. Let (G,k) be a YES-instance of (a,d)-HITTING SET. Then
there is a set A(S with DADƒk that hits each element c of C at
least g(c) times. Assume that there are sets B and N as described in
the reduction rule and that for some i[½1,a  we have that DNiDwk.
Let ANi be the subset of A that hits Ni. Assume further that
ANi 6(B, then for each n[Ni there is at least one other vertex in
Figure 3. Minimal hitting set hitting only breast cancer cell lines. Excluding the disputed MDA-N cell line. In this case the hitting set is much
less clearly separated, though two of the cell lines are now hit twice. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g003
Table 5. Minimal hitting set targeting breast cancer but
allowing other cell lines to be hit.
NSC Number Compound Name
652903 Saframycin AR1(AH2)
685006 2-imino-8-methoxy-N-phenylchromene-3-carboxamide
733504 Everolimus/Afinitor
Minimal hitting set hitting breast cancer cell lines at least once, and all other cell
lines zero times.
doi:10.1371/journal.pone.0013055.t005
Hitting Set and Drug Therapy
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70929 Hedamycin
156565 1-hydroxy-4-[4-(2-hydroxyethyl)anilino]anthracene-9,10-dione
628503 Docetaxel
697188 2-(4-methoxyphenyl)-5-[8-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]octyl]-1,3,4-oxadiazole
732011 21-(2-N,N-Diethylaminoethyl)oxy-7.alpha.-methyl-19-norpregna-1,3,5(10)-triene-3-O-sulfamate
734235 isoindolo[1,2-a]quinoxalin-4(5H)-one
Minimal hitting set hitting breast cancer cell lines at least once, and all other cell lines zero times.
doi:10.1371/journal.pone.0013055.t006
Figure 5. Minimal hitting set hitting breast cancer cell lines twice. Including the disputed MDA-N cell line. In this case the breast cancer cell
lines separate neatly into two groups, with the first group forming a cycle and the second group forming a complete bipartite graph. Only cell lines
with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g005
Table 7. Minimal hitting set hitting breast cancer twice, and no others, without MDA-N.
156565 1-hydroxy-4-[4-(2-hydroxyethyl)anilino]anthracene-9,10-dione
630678 Streptomyces antibiotic
697188 2-(4-methoxyphenyl)-5-[8-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]octyl]-1,3,4-oxadiazole
698400 5-(1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydrobenzo[a]phenanthridine
732011 21-(2-N,N-Diethylaminoethyl)oxy-7.alpha.-methyl-19-norpregna-1,3,5(10)-triene-3-O-sulfamate
Minimal hitting set hitting breast cancer cell lines at least once, and all other cell lines zero times.
doi:10.1371/journal.pone.0013055.t007
Figure 4. Minimal hitting set hitting only breast cancer cell lines. Excluding the disputed MDA-N cell line. In this case we allow non-breast
cancer cell lines to be hit at most once. By relaxing the restriction on hitting non-breast cancer cell lines, we obtain a hitting set which hits more of
the breast cancer cell lines repeatedly. The trade-off being that other cell lines are also affected, increasingly the likelihood that non-cancerous cells
are also affected by the treatment, as the compounds are less specific to a particular genetic signature. Only cell lines with at least one adjacent
compound are shown.
doi:10.1371/journal.pone.0013055.g004
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that (G,k) is a YES-instance.
Therefore the set Ni must be hit by B, so we may restrict our
search to the intersection. .
Lemma 5 Reduction Rule 4 can be computed in polynomial time.
Proof. Given a set of vertices B(N(s) for some s[S with
DBD~d{1, we construct an auxiliary graph G’ by taking for each i
the subgraph of G induced by the vertices N(Ni)\B. If there is a
Figure 6. Minimal hitting set hitting breast cancer cell lines twice. Excluding the disputed MDA-N cell line. Without the MDA-N cell line, the
breast cancer cell lines do not separate, although the complete bipartite component is a subgraph of this graph, however we gain a greater number
of hits per cell line in this case. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g006
Table 8. Minimal hitting set targeting melanoma twice, without MDA-N.
624206 N-[2-[(4-chlorophenyl)methyldisulfanyl]ethyl]decan-1-amine hydrochloride
646807 2-(2-Isonicotinoylhydrazino)-N-(3-methyl-1,4-dioxo-1,4-dihydro-2-naphthalenyl)-2-oxoacetamide
674092 2-phenyl-N-[3-[4-[3-[(2-phenylquinoline-4-carbonyl)amino]propyl]piperazin-1-yl]propyl]quinoline-4-carboxamide hydrochloride
677944 6-[2-(4-hydroxy-3-methoxyphenyl)ethylamino]quinoline-5,8-dione
697989 dicopper 2-acetyloxy-3,5-di(propan-2-yl)benzoate
708559 2-(3,4-dichlorophenyl)-N-methyl-N-[3-[methyl(3-pyrrolidin-1-ylpropyl)amino]propyl]acetamide
Minimal hitting set hitting melanoma cell lines at least twice and no others. This result does not include MDA-N as a melanoma cell line.
doi:10.1371/journal.pone.0013055.t008
Figure 7. Minimal hitting set hitting melanoma cell lines at least 2 and no other cell lines. This hitting set also maximizes the number of
hits on the melanoma cell lines. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g007
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vertices from S form the required set with pairwise neighbohood
intersection B.
As d is a constant, we can iterate over all sets of vertices of size
d{1 in time O(DSD:d). The matchings can be computed in time
O(a:DN(B)|(N(N(B)\B))D
3=2).
Definition 6 (Weakly Related Vertices) Given two vertices
s,t[C, s and t are weakly related if DN(s)\N(t)Dƒd{1, and both
N(s) 6(N(t) and N(t) 6(N(s).
Let W(C be a maximal set of pairwise weakly related
vertices. Let B(S be a set of vertices, and denote by WB the set
of vertices of W whose neighborhood is a superset of B. Further
denote by WB,i the subset of WB where for each v[WB,i we have
g(v)~i.
Reduction Rule 5: Compute a maximal collection W of
pairwise weakly related vertices. If DWDwakd apply the following
algorithm:
for j~d{1 downto 1 do
for t~a downto 1 do
for each set B(N(v) where v[W and DBD~j do
if DWB,tDwkd{j then
Add a vertex c to C, edges such that N(c)~’ and set
g(c)~t.
Delete WB,t from G.
Figure 8. Minimal hitting set hitting melanoma cell lines at least 2 and no other cell lines. Including the disputed MDA-N cell line. It is
interesting to note that including MDA-N as a melanoma cell line rather than a breast cancer cell line reduces the size of the minimal hitting set from
6 to 5. This hitting set also maximizes the number of hits on the melanoma cell lines. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g008
Table 9. Minimal hitting set targeting melanoma, without MDA-N.
NSC Number Compound Name
646807 2-(2-Isonicotinoylhydrazino)-N-(3-methyl-1,4-dioxo-1,4-dihydro-2-naphthalenyl)-2-oxoacetamide
656238 2-Methyl-4,8-dihydrobenzo[1,2-b:5,4-b9]dithiophene-4,8-dione
741078 AZD6244 (ARRY-142886)
Minimal hitting set hitting melanoma cell lines at least twice, all others at most once, maximizing the degree of the melanoma cell line vertices.
doi:10.1371/journal.pone.0013055.t009
Table 10. Minimal hitting set targeting melanoma, with MDA-N.
NSC Number Compound Name
361127 Destruxin E
624206 N-[2-[(4-chlorophenyl)methyldisulfanyl]ethyl]decan-1-amine hydrochloride
656238 2-Methyl-4,8-dihydrobenzo[1,2-b:5,4-b9]dithiophene-4,8-dione
Minimal hitting set hitting melanoma cell lines at least twice, all others at most once, maximizing the degree of the melanoma cell line vertices.
doi:10.1371/journal.pone.0013055.t010
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Proof. We defer the proof of the bound on the size of W until the
proof of Lemma 8.
Let (G,k) be a YES-instance of (a,d)-HITTING SET. Then there is
a set A(S that hits S sufficiently. For sets of size d{1, Reduction
Rule 4 proves the soundness of the first iteration of the outer loop.
For each other iteration, assume that the iteration for sets of size
j holds, then let B be set of size j{1 where DWB,tDwkd{jz1 for
some t.I fDA\BDvt then by the pigeon hole principle there is
some vertex v[A that is in at least kd{j neighborhoods of vertices
in WB,t, but then B|fvg is a set that is the intersection of at least
kd{j neighborhoods of vertices in some subset of W, contradicting
the correctness of the previous iteration. Therefore the entire set of
vertices hitting each WB,t vertex is contained within B if
DWB,tDwkd{j, so we may replace WB,t with a single vertex.
Note also that for each element of W there is at most 2d sets B,
so we may iterate through all sets in time O(ad2d:DWD), so we can
perform the replacements in polynomial time.
Lemma 8 If (G,k) is a YES-instance of (a,d)-HITTING SET, reduced
under Reduction Rules 1 to 5, then DV(G)Dƒ(dz1)akd.
Proof.I f(G,k) is a YES-instance of (a,d)-HITTING SET, then there
is a set A(S such that for every s[S we have DN(s)\AD§g(s)
with DADƒk.
Claim 9 C~W.
By construction, every vertex in C with degree at most d{1 is
in W. Assume there is some c[C with d(c)~d and c 6[W, then
Figure 9. Minimal hitting set hitting melanoma cell lines at least 2 and all other cell lines at most once. For this we consider MDA-N as a
non-melanoma cell line, however it is also hit by the hitting set, though only once. This hitting set also maximizes the number of hits on the
melanoma cell lines. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g009
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but then as the degree of any vertex in C is at most d,
N(c)~N(c’), and Reduction Rule 3 would apply. Therefore there
are no vertices from C not in W.
Claim 10 DWDƒakd.
As A hits each vertex of W at least once, by Reduction Rule 5
each element of A as a singleton is in the neighborhood of at most
akd{1 vertices from C. Therefore DWDƒDAD:akd{1ƒakd.
Figure 10. Minimal hitting set hitting melanoma cell lines at least 2 and all other cell lines at most once. Including MDA-N as a
melanoma cell line. The key difference with the case where we consider MDA-N to be a non-melanoma cell line is that in this case we obtain a hitting
set that hits the melanoma cell lines slightly more. Only cell lines with at least one adjacent compound are shown.
doi:10.1371/journal.pone.0013055.g010
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has degree at most d,t h e r ea r ea tm o s tadkd vertices in S,a n dt h e
bound follows.
Theorem 11 (a,d)-HITTING SET is fixed-parameter tractable with
parameter k and has a kernel of size at most adkd.
We note that although d must be a constant to obtain a
polynomial time kernelization, a may be alternatively given as an
additional parameter, without change to the kernelization.
This kernelization may be extended to an even more general
version of the problem, where we not only specify lower bounds
for the number of hits, but also upper bounds:
(a,b,d)-HITTING SET
Instance: A bipartite graph G~(S ] C,E) where for all c[C
we have d(c)ƒd, two hitting functions g1 : C?½0,a  and
g2 : C?½0,b  and an integer k.
Question: Is there a set S’(S with DS’Dƒk such that for every
c[C we have g2(c)§DN(c)\S’D§g1(c)?
Corollary 12 (a,b,d)-HITTING SET is fixed-parameter tractable with
parameter k and has a kernel of size at most adkd.
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